Reem Karmali

Associate Professor, Medicine, Hematology Oncology Division

Emailreem.karmali@northwestern.edu

Source: Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Training Experience

2009	Residency, Rush University Medical Center
2012	Fellowship, Rush University Medical Center

Education/Academic qualification

MS, Rush University

… → 2012

MD, Western University

… → 2006

Fingerprint

Dive into the research topics where Reem Karmali is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

6 Finished
15 Active

Prot #JCAR017-EAP-001: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial Release
Karmali, R.
DrugDev Inc., Juno Therapeutics, Inc.
2/3/21 → 2/3/24
Project: Research project
Prot #KT-US-471-0119: A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)
Karmali, R.
Gilead Sciences, Inc., Kite Pharma, Inc.
10/14/20 → 10/14/23
Project: Research project
Prot #RPM-CART-001: An Observational Study to Evaluate a Temperature Monitoring Device in Subjects Receiving CAR-T Therapy
Karmali, R.
Celgene Corporation
9/28/20 → 9/28/23
Project: Research project
Prot #JCAR017-FOL-001: A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHL) (Transcend FL)
Karmali, R.
ICON Clinical Research, LLC, Celgene Corporation
7/27/20 → 7/27/23
Project: Research project
Prot #JCAR017-BCM-003: A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TR
Karmali, R.
ICON Clinical Research, LLC, Celgene Corporation
10/21/19 → 10/21/22
Project: Research project

894 Citations
43 Article
4 Review article
1 Chapter

Burkitt Lymphoma International Prognostic Index
Olszewski, A. J., Jakobsen, L. H., Collins, G. P., Cwynarski, K., Bachanova, V., Blum, K. A., Boughan, K. M., Bower, M., Dalla Pria, A., Danilov, A., David, K. A., Diefenbach, C., Ellin, F., Epperla, N., Farooq, U., Feldman, T. A., Gerrie, A. S., Jagadeesh, D., Kamdar, M., Karmali, R. & 29 others, Kassam, S., Kenkre, V. P., Khan, N., Kim, S. H., Klein, A. K., Lossos, I. S., Lunning, M. A., Martin, P., Martinez-Calle, N., Montoto, S., Naik, S., Palmisiano, N., Peace, D., Phillips, E. H., Phillips, T. J., Portell, C. A., Reddy, N., Santarsieri, A., Sarraf Yazdy, M., Smeland, K. B., Smith, S. E., Smith, S. D., Sundaram, S., Zayac, A. S., Zhang, X. Y., Zhu, C., Cheah, C. Y., El-Galaly, T. C. & Evens, A. M., Apr 1 2021, In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39, 10, p. 1129-1138 10 p.
Research output: Contribution to journal › Article › peer-review
Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers
Evens, A. M., Danilov, A., Jagadeesh, D., Sperling, A., Kim, S. H., Vaca, R., Wei, C., Rector, D., Sundaram, S., Reddy, N., Lin, Y., Farooq, U., D'Angelo, C., Bond, D. A., Berg, S., Churnetski, M. C., Godara, A., Khan, N., Choi, Y. K., Yazdy, M. & 38 others, Rabinovich, E., Varma, G., Karmali, R., Mian, A., Savani, M., Burkart, M., Martin, P., Ren, A., Chauhan, A., Diefenbach, C., Straker-Edwards, A., Klein, A. K., Blum, K. A., Boughan, K. M., Smith, S. E., Haverkos, B. M., Orellana-Noia, V. M., Kenkre, V. P., Zayac, A., Ramdial, J., Maliske, S. M., Epperla, N., Venugopal, P., Feldman, T. A., Smith, S. D., Stadnik, A., David, K. A., Naik, S., Lossos, I. S., Lunning, M. A., Caimi, P., Kamdar, M., Palmisiano, N., Bachanova, V., Portell, C. A., Phillips, T., Olszewski, A. J. & Alderuccio, J. P., Jan 21 2021, In: Blood. 137, 3, p. 374-386 13 p.
Research output: Contribution to journal › Article › peer-review
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Allen, P. B., Savas, H., Evens, A. M., Advani, R. H., Palmer, B., Pro, B., Karmali, R., Mou, E., Bearden, J., Dillehay, G., Bayer, R. A., Eisner, R. M., Chmiel, J. S., O'Shea, K., Gordon, L. I. & Winter, J. N., Mar 11 2021, In: Blood. 137, 10, p. 1318-1326 9 p.
Research output: Contribution to journal › Article › peer-review
2 Scopus citations
Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis
Rink, J. S., Lin, A. Y., McMahon, K. M., Calvert, A. E., Yang, S., Taxter, T., Moreira, J., Chadburn, A., Behdad, A., Karmali, R., Shad Thaxton, C. & Gordon, L. I., Jan 1 2021, In: Journal of Biological Chemistry. 296, 100100.
Research output: Contribution to journal › Article › peer-review

Open Access
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
Carreau, N. A., Pail, O., Armand, P., Merryman, R., Advani, R. H., Spinner, M. A., Herrera, A., Chen, R., Tomassetti, S., Ramchandren, R., Hamid, M. S., Assouline, S., Santiago, R., Wagner-Johnston, N., Paul, S., Svoboda, J., Bair, S., Barta, S., Liu, Y., Nathan, S. & 14 others, Karmali, R., Burkart, M., Torka, P., David, K., Wei, C., Lansigan, F., Emery, L., Persky, D., Smith, S., Godfrey, J., Chavez, J., Xia, Y., Troxel, A. B. & Diefenbach, C., Oct 1 2020, In: Oncologist. 25, 10, p. 878-885 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations